Case study

Technology as a weapon against antibiotic resistance

Project “Dartbac"

The coronavirus pandemic has claimed more than a million lives. Though this is certainly dramatic, the rise of the silent killer antibiotic resistance (AMR) is even more threatening and will claim many more victims. The expectation is that this figure will ultimately climb to more than ten million a year worldwide. Researcher Chris Arts of Maastricht UMC+ is leading a major international study into alternatives to antibiotics, technological solutions and increased awareness of AMR. “We are heading for disaster if we do not recognize and address this problem.”

Chris Arts does understand that the last thing we all need is a new nightmare scenario. After all, the world already has its hands full with COVID-19. “Absolutely true,” he says, “but we’ll beat the virus, sooner or later. Resistance to antibiotics is even more serious, however. Bacteria are even more stubborn than viruses, they don’t weaken in strength and they also mutate. The only way to fight many serious infections is with antibiotics. If these drugs stop working, patients have to rely on their own immune systems. This often doesn’t end well, leaving patients with serious permanent damage or even causing their death. For years, we have been seeing more and more bacteria becoming resistant to antibiotics and we have been warning about the risk of an epidemic for a long time. I hate to have to say it, but this will happen.”


The orthopedist/researcher, who graduated as a kinesiology scientist in Maastricht and obtained his doctorate in Nijmegen, shows a map depicting the resistance to antibiotics for the life-threatening MRSA bacteria, among others. Several regions in Southern Europe and America in particular are turning an alarming shade of red. “This means that half the people who get infected can’t be treated successfully with antibiotics. The figures are a lot more encouraging in the Netherlands and Scandinavia. Firstly, because these countries are much more cautious about the use of antibiotics and we are relatively strict when it comes to adding antibiotics to animal feed. The cause of resistance is actually very simple: because we use too many antibiotics, they can no longer kill the bacteria. In France, Spain and Portugal it’s easy to buy antibiotics. Six courses a year for a cold, diarrhea or other ailment; this is not an exception in these countries. People often don’t finish these courses of antibiotics and the wrong types are used. Put all of these factors together and you get an explosive increase in resistance, also because there are hardly any new antibiotic variants being developed anymore. And don’t assume we’re safe here in the Netherlands; resistant bacteria are coming across our borders through tourism or business travel.”


The consequences are becoming more dire by the day. “Take hospital patients who develop an infection after surgery; I see them in my own practice. And their numbers are only rising. This isn’t immediately life-threatening, but it can be when antibiotics stop working. When this happens, a standard hip surgery, knee replacement or a thoracic procedure can prove fatal. At a minimum, it can lead to longer periods of care or admission to intensive care units and subsequent extended periods of rehabilitation. In Europe, 400,000 people are already ending up in intensive care because antibiotics aren’t working. Given the current growth rates, this number is likely to rapidly increase tenfold. Extrapolate this to the Netherlands, and there will be more pressure on IC units and hospital care than we’re now seeing from COVID-19. Now try to calculate how much this will cost. It’s in the billions.”


In spite of these shocking figures, awareness of the problem is still not very widespread. The use of antibiotics is only increasing. The Netherlands is an exception in this regard. Last year, the NWO awarded a subsidy of 9.8 million Euros to the Dutch Antimicrobial Resistance Technology development and Biofilm Assessment Consortium, or DARTBAC for short. The objective of this international alliance of more than 25 scientific institutes and entrepreneurs is to provide solutions. This is a consortium that includes Maastricht UMC+ as the secretary, and Chris Arts as a project leader. “It’s no coincidence that we’re in the lead,” says the Brabant native, who co-directs a lab in Maastricht with 35 other orthopedic researchers and also conducts technical research at TU Eindhoven one day a week. “Here in South Limburg, we have a great ecosystem thanks to the Brightlands campuses. We have the best imaging facilities here, along with top researchers and institutes specializing in materials research. There are also crossovers with organizations in Germany and Belgium. We are able to conceive, develop and apply technological solutions here.”


Technological solutions for resistance. So the goal isn’t new antibiotics? “At DARTBAC, we’re looking at combinations using antibiotics and other substances such as metals, and we’re also trying to create broad awareness. The focus here in Maastricht and the local area is on the development of materials that repel or destroy bacteria. Examples include hip and knee implants, plates used for fractures, but also materials for IVs, catheters, pacemakers, stents, and so on. There’s always a chance of infection with any surgery, but we hope to minimize that risk and prevent the need for antibiotics. Prevention is always better than cure. We are developing coatings with antibiotics that attack the bacteria very locally; we are looking for materials that bacteria cannot affect, with a specific focus on biological materials. The developments at the campuses and MUMC+ are promising. For example, they’re working on a coating with minuscule dots which make it impossible for bacteria to adhere to and thus adversely affect bone or tissue. We use the M4I scanners, the best in Europe, to test whether or not this works.”

Slowing down

Over the next six years, the duration of the DARTBAC project, Chris Arts wants to clinically validate three groundbreaking technological solutions. At least ten more researchers will be hired in Maastricht to accelerate the research. “This definitely does not mean the danger has been averted. Technology is only part of the solution. We’ll be very happy if we can just slow resistance down.” Awareness can further accelerate the acceptance of technology both in the near and distant future.

Source: Website Brightlands Maastricht Health Campus


Principal Investigator: Dr. Chris Arts

In the media

  • Dartbac logo

    Consortium receives €11 million grant in the fight against antibiotic resistance

    Wednesday, November 25, 2020

    As part of the National Science Agenda, NWO is providing a grant of 9.8 million euros to the DARTBAC project: Dutch Antimicrobial Resistance Technology development and Biofilm Assessment Consortium. An international interdisciplinary consortium led by MUMC+/CAPHRI researcher dr. Chris Arts will spend the next 6 years researching new technological solutions to the explosively growing problem of antimicrobial resistance (AMR).

    Read more

Involved partners

DARTBAC is an interdisciplinary, 23 partner consortium consisting of:

  • Academic partners: Maastricht University, Maastricht UMC+, Amsterdam UMC, Leiden UMC, the National Institute for Public Health and the Environment (RIVM), Delft University of Technology, Eindhoven University of Technology, UMC Groningen, UMC Utrecht and the University of Amsterdam.

  • Industry partners: B. Braun Aesculap (Germany), BiosparQ (Netherlands), Bonalive (Finland), CAM Bioceramics (Netherlands), DSM (Netherlands), MadamTherapeutics (Netherlands), OS-1 (Netherlands), PCI Biotech (Norway) and Healthcare Innovations Netherlands (Netherlands).

  • Other partners: AMR-Insights, Federation Medical Specialists Knowledge Institute, Dutch Orthopaedic Association and ReumaNederland.

By involving social sciences, communication sciences, materials sciences, medical sciences as well as medical specialist organizations, the RIVM, communication experts, health funds and industrial partners straight from the start of the project, we create the opportunity to raise awareness around AMR and to develop and clinically apply possible material technical solutions more quickly.
Dartbac partners

Research team (Maastricht UMC+)

Involved research lines

  • Functioning, Participation and Rehabilitation
  • Promoting Health and Personalised Care 

Our most important societal relevant output

Dartbac kaartspel 2

Antibiotic resistance awareness card game

Our most important scientific output